Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous gp96 vaccination in liver and pancreatic cancer
NCT02133079Phase 2Unknown
- Sponsor
- Cure & Sure Biotech
- Start
- Mar 2012
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of vitespen in liver cancer, pancreatic adenocarcinoma (PDAC), sponsored by Cure & Sure Biotech. Status: unknown.
02
Drugs
vitespen
03
Conditions
liver cancerpancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02133079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02133079.